NewAmsterdam Pharma Company N.V.

Analysts from Leerink Partners maintain Buy ratings on Vir Biotechnology (VIR) with a $18.00 target and Sell on Moderna (MRNA) with no target specified. The consensus for VIR is a Moderate Buy with a $32.67 target, while Moderna has a Moderate Buy consensus with a $97.62 target.

Bio-pharma advances in endocrinology, dermatology, cardiovascular, oncology, rare diseases, pulmonology, gastroenterology, and neurology highlight promising therapies like Eli Lilly’s orforglipron, Amgen’s MariTide, Novo Nordisk’s oral semaglutide, Johnson & Johnson’s JNJ-2113, Sanofi’s amlitelimab, Ionis’s olezarsen, BridgeBio’s acoramidis, NewAmsterdam Pharma’s obicetrapib, Jazz Pharmaceuticals’ zanidatamab, Syndax’s revumenib, Merus’ zenocutuzumab, Johnson & Johnson’s nipocalimab, Novo Nordisk’s Mim8, Solid Biosciences’ SGT-003, Merck’s sotatercept, Johnson & Johnson’s Tremfya, and Crossject’s Zepizure, with analyses including clinical data, revenue forecasts, and expected launch dates.

Positive topline data from Phase 3 BROOKLYN trial shows obicetrapib significantly reduces LDL-C by 36.3% at 12 weeks and 41.5% at 52 weeks in HeFH patients, with well-tolerated safety profile. Over 50% achieved LDL-C below 70 mg/dl, and reductions in non-HDL-C, ApoB, and Lp(a) were statistically significant. The trial evaluated 10 mg obicetrapib vs. placebo in 354 patients with HeFH on maximally tolerated lipid-lowering therapy.

NewAmsterdam Pharma updates on obicetrapib's Phase 3 trials: BROOKLYN (HeFH) data expected 3Q 2024, BROADWAY (ASCVD) 4Q 2024, and PREVAIL CVOT enrollment completion 1Q 2024 with data in 2026. Plans to start TANDEM trial (obicetrapib + ezetimibe) 1Q 2024, data expected 1Q 2025. Well-funded through 2026.